<p>The invention relates to the regulation of the immune system, and in particular to the finding that the CLEC9a molecule is a marker for dendritic cells which are capable of cross-presenting extracellular antigens via the MHC class I pathway. This makes them particularly suitable for generation of cytotoxic T lymphocyte responses. Materials and methods are provided both for the induction of immune responses against target antigens, and for the inhibition or suppression of undesirable immune responses in which these cells are involved.</p>
申请公布号
EP2185586(B1)
申请公布日期
2015.10.14
申请号
EP20080776024
申请日期
2008.07.21
申请人
CANCER RESEARCH TECHNOLOGY LIMITED
发明人
SANCHO-MADRID, DAVID;SCHULZ, OLIVER;ROGERS, NEIL CHARLES;REIS E SOUSA, CAETANO;PENNINGTON, DANIEL;JOFFRE, OLIVIER PIERRE